Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 8 | 1,779 | 33% |
| 2020 | 7 | 1,494 | 36% |
| 2021 | 6 |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Jersey; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 15 | 2,669−5%/yr | −5%/yr | 1.5 | 0% | 2,770 in 2030+0.6%/yr |
| Pennsylvania | 12 | 2,424 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 76 | 5,785−0.6%/yr | −0.6%/yr | 5.81.0× | 4% | 6,020 in 2030+0.7%/yr |
| Cholecystectomy & appendectomy |
Colorectal resection in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
| 2024 |
| 1,527 |
| 45% |
| 2025 est. | ≈ 1,630 | – |
| 2026 est. | ≈ 1,650 | – |
| 1,524 |
| 39% |
| 2022 | 9 | 1,534 | 41% |
| 2023 | 11 | 1,627 | 43% |
| 2024 | 8 | 1,527 | 45% |
| 2025 from claims | – | 1,628 1,494–1,722 | 46% |
| 2026 forecast | – | 1,652 1,454–1,907 | 46% |
| 2027 forecast | – | 1,673 1,431–1,994 | 47% |
| 2028 forecast | – | 1,695 1,414–2,075 | 47% |
| 2029 forecast | – | 1,716 1,402–2,152 | 47% |
| 2030 forecast | – | 1,738 1,392–2,227 | 48% |
In 2025, 95% inpatient hospital, 5% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| −5.6%/yr |
| 1.8 |
| 0% |
| 2,120 in 2030−2.2%/yr |
| Massachusetts | 10 | 1,485−3.1%/yr | −3.1%/yr | 1.6 | 0% | 1,660 in 2030+1.9%/yr |
| Connecticut | 2 | 469−8.4%/yr | −8.4%/yr | 1.5 | 0% | 480 in 2030+0.5%/yr |
| New Hampshire | 1 | 334−4.2%/yr | −4.2%/yr | 1.5 | 0% | 420 in 2030+3.9%/yr |
| Maine | 1 | 264−7.9%/yr | −7.9%/yr | 1.7 | 0% | 170 in 2030−7.1%/yr |
| Vermont | 0 | 141+1.5%/yr | +1.5%/yr | 1.3 | 0% | 150 in 2030+1%/yr |
| Rhode Island | 0 | 116−12%/yr | −12%/yr | 1.3 | 0% | 230 in 2030+12%/yr |
| 81 |
| 3,400−3.2%/yr |
| −3.2%/yr |
| 3.30.9× |
| 1% |
| 3,540 in 2030+0.7%/yr |
| Antireflux & hiatal hernia surgery | 7 | 492+0.3%/yr | +0.3%/yr | 0.50.7× | 0% | 540 in 2030+1.6%/yr |
| Breast reconstruction | 1 | 481−3.3%/yr | −3.3%/yr | 0.51.1× | 0% | 370 in 2030−4.1%/yr |
| Bariatric surgery | 0 | 168−20%/yr | −20%/yr | 0.20.9× | 0% | 120 in 2030−5%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Intuitive Surgical leads with 70% of company spending on these surgeons in 2025, −1 pts on 2024.
In 2025, 4 companies reported engagement with New Jersey’s surgeons worth $203K in consulting, speaking, meals and travel tied to these products, about $25K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.